Abstract
Purpose: Advances in tumor biology and clinical trials indicate that p53 transfer is an alternative therapy for head and neck squamous cell carcinoma. The current inquiry was a single-center, phase I study of the rAd-p53 repeated intraepithelial injection for dysplastic oral leukoplakia (OLK), the most common precursor of the oral squamous cell carcinoma. The primary objective was to determine the feasibility and safety of this therapy, while the secondary objective was to observe biological responses and preliminary curative effects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
